Bone Fracture - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Bone Fracture - Pipeline Review, H1 2016', provides an overview of the Bone Fracture pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Fracture, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Fracture - The report reviews pipeline therapeutics for Bone Fracture by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Bone Fracture therapeutics and enlists all their major and minor projects - The report assesses Bone Fracture therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Bone Fracture Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Bone Fracture - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Bone Fracture Overview 9 Therapeutics Development 10 Pipeline Products for Bone Fracture - Overview 10 Pipeline Products for Bone Fracture - Comparative Analysis 11 Bone Fracture - Therapeutics under Development by Companies 12 Bone Fracture - Therapeutics under Investigation by Universities/Institutes 13 Bone Fracture - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Bone Fracture - Products under Development by Companies 16 Bone Fracture - Products under Investigation by Universities/Institutes 17 Bone Fracture - Companies Involved in Therapeutics Development 18 Arcarios BV 18 AstraZeneca Plc 19 Biogenomics Limited 20 BiologicsMD, Inc. 21 Biopharm GmbH 22 Bone Therapeutics SA 23 ethris GmbH 24 Juventas Therapeutics, Inc. 25 Kuros Biosciences AG 26 Novartis AG 27 TissueGene, Inc. 28 Viking Therapeutics, Inc. 29 Bone Fracture - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 ALLOB - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 AZD-2858 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 bimagrumab - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 BMD-1221 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Cyndacel-M - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 denosumab biosimilar - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 dibotermin alfa - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Gene Therapy for Bone Fracture - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 JVS-200 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 KAL-436 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 KUR-111 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 KUR-113 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 LWnt-3a - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Recombinant Protein to Activate TNF-Alpha for Fracture Repair - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Stem Cell Therapy for Fracture Repair - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 TG-B - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 VK-5211 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Bone Fracture - Recent Pipeline Updates 68 Bone Fracture - Dormant Projects 74 Bone Fracture - Discontinued Products 75 Bone Fracture - Product Development Milestones 76 Featured News & Press Releases 76 Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture 76 Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects 76 Oct 09, 2015: Kuros Presents Results of Phase IIB Study with KUR-111 at the 2015 Orthopaedic Trauma Association Annual Meeting 77 Sep 01, 2015: Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator, for Acute Hip Fracture 78 Jul 14, 2015: Viking Therapeutics Submits Investigational New Drug (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SARM), in Acute Hip Fracture 78 Aug 29, 2013: Researcher Awarded $5 Million to Advance Future Stem Cell Treatments for Segmental Bone Fractures 79 Jan 24, 2011: Kuros Reports One Year Data From Phase IIb Study With KUR-111 80 Jun 02, 2010: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-113 In Patients With Tibial Shaft Fractures 81 Mar 15, 2010: Kuros Meets Primary Efficacy Endpoint In Phase IIb Study With KUR-111 81 Jun 08, 2009: Kuros Completes Patient Recruitment In A Phase IIb Trial Of KUR-111 In Patients With Tibial Plateau Fractures 82 Appendix 83 Methodology 83 Coverage 83 Secondary Research 83 Primary Research 83 Expert Panel Validation 83 Contact Us 83 Disclaimer 84
List of Tables
Number of Products under Development for Bone Fracture, H1 2016 10 Number of Products under Development for Bone Fracture - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Bone Fracture - Pipeline by Arcarios BV, H1 2016 18 Bone Fracture - Pipeline by AstraZeneca Plc, H1 2016 19 Bone Fracture - Pipeline by Biogenomics Limited, H1 2016 20 Bone Fracture - Pipeline by BiologicsMD, Inc., H1 2016 21 Bone Fracture - Pipeline by Biopharm GmbH, H1 2016 22 Bone Fracture - Pipeline by Bone Therapeutics SA, H1 2016 23 Bone Fracture - Pipeline by ethris GmbH, H1 2016 24 Bone Fracture - Pipeline by Juventas Therapeutics, Inc., H1 2016 25 Bone Fracture - Pipeline by Kuros Biosciences AG, H1 2016 26 Bone Fracture - Pipeline by Novartis AG, H1 2016 27 Bone Fracture - Pipeline by TissueGene, Inc., H1 2016 28 Bone Fracture - Pipeline by Viking Therapeutics, Inc., H1 2016 29 Assessment by Monotherapy Products, H1 2016 30 Number of Products by Stage and Target, H1 2016 32 Number of Products by Stage and Mechanism of Action, H1 2016 34 Number of Products by Stage and Route of Administration, H1 2016 36 Number of Products by Stage and Molecule Type, H1 2016 38 Bone Fracture Therapeutics - Recent Pipeline Updates, H1 2016 68 Bone Fracture - Dormant Projects, H1 2016 74 Bone Fracture - Discontinued Products, H1 2016 75
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.